Wellbutrin (bupropion) works primarily by blocking two transporters in your brain: the dopamine transporter and the norepinephrine transporter. This makes it fundamentally different from most antidepressants, which target serotonin. Bupropion also acts as an antagonist at nicotinic acetylcholine receptors, which helps explain its role in smoking cessation. The receptor profile is surprisingly clean, with almost no activity at serotonin, histamine, or muscarinic receptors, and that selectivity accounts for much of what people notice (and don’t notice) when they take it.
Dopamine and Norepinephrine Reuptake Inhibition
The core mechanism of bupropion is dual reuptake inhibition: it blocks the proteins that vacuum up dopamine and norepinephrine from the space between neurons, allowing those chemicals to linger longer and keep signaling. Preclinical and clinical evidence confirms that bupropion acts through this dual inhibition and is devoid of clinically significant serotonergic effects or direct effects on postsynaptic receptors.1PubMed Central. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor This is what earns bupropion the technical label “NDRI” (norepinephrine-dopamine reuptake inhibitor), a category it essentially occupies alone among commonly prescribed antidepressants.
One thing that puzzled researchers for years is that bupropion’s dopamine transporter occupancy at standard clinical doses is surprisingly low. Positron emission tomography studies in humans found that bupropion and its metabolites occupy only about 20 to 25 percent of striatal dopamine transporter sites at typical doses.2PubMed Central. Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: An [11C]raclopride PET study A separate imaging study confirmed this range, finding about 26 percent occupancy three hours after the last dose of sustained-release bupropion, a level that held steady through 24 hours.3PubMed. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography
That 20-to-26 percent figure is modest compared to drugs of abuse that flood the dopamine system with transporter occupancies well above 50 percent. The implication is that bupropion produces a gentle, sustained nudge in dopamine availability rather than a surge. This likely explains why bupropion does not produce the euphoria or strong reinforcing effects associated with stimulants, even though it technically works on some of the same machinery.
Why Serotonin Stays Out of the Picture
Most antidepressants on the market, from fluoxetine (Prozac) to sertraline (Zoloft) to duloxetine (Cymbalta), include serotonin reuptake inhibition as a major part of their mechanism. Bupropion does not. It has no meaningful effect on serotonin reuptake and no significant binding at serotonergic receptors.1PubMed Central. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor
This absence matters a lot in practice. Many of the most common complaints about SSRIs and SNRIs, including sexual dysfunction, weight gain, and emotional blunting, are linked in varying degrees to serotonergic activity. Bupropion’s clean miss on the serotonin system is a major reason clinicians reach for it when those side effects are a concern. It also lacks significant activity at histamine H1 receptors (which tend to cause sedation and weight gain when blocked) and muscarinic acetylcholine receptors (which tend to cause dry mouth, constipation, and cognitive fog when blocked). The result is an unusually lean side-effect profile for an antidepressant. People switching from an SSRI to bupropion frequently describe feeling more alert and less emotionally dampened, which tracks with the pharmacology.
Nicotinic Receptor Antagonism
Beyond its transporter-blocking role, bupropion does something that most antidepressants do not: it blocks nicotinic acetylcholine receptors. These are the receptors that nicotine itself activates, and bupropion works as a noncompetitive antagonist, meaning it cannot be overcome simply by adding more nicotine or acetylcholine.4PubMed. Bupropion is a nicotinic antagonist This action is broad-spectrum, affecting multiple subtypes of nicotinic receptors.5PubMed Central. Bupropion inhibits the cellular effects of nicotine in the ventral tegmental area
The way bupropion interferes with nicotinic receptors is not a simple “lock and key” block. Research on muscle-type nicotinic receptors showed that bupropion binds to the receptor in its resting state, decreasing the likelihood that the ion channel will open in the first place. For the fraction of channels that still manage to open, bupropion accelerates their transition into a desensitized (shut-down) state. The binding site sits inside the ion channel pore itself, wedged between specific structural rings of the channel.6PubMed Central. Interaction of bupropion with muscle-type nicotinic acetylcholine receptors in different conformational states
In the brain’s reward circuitry, this has a specific consequence. Brain-slice experiments showed that clinically relevant concentrations of bupropion dramatically reduced nicotine’s ability to excite dopamine neurons in the ventral tegmental area, a key region for reward and motivation.5PubMed Central. Bupropion inhibits the cellular effects of nicotine in the ventral tegmental area This is thought to be one of the mechanisms behind bupropion’s effectiveness for smoking cessation: by blunting the rewarding hit of nicotine, it may help prevent relapse in people who are trying to quit.7PubMed. How does bupropion work as a smoking cessation aid? The drug was approved under the brand name Zyban for this purpose, and the nicotinic antagonism is the pharmacological thread connecting its antidepressant and smoking-cessation uses.
Active Metabolites Do a Lot of the Work
When you swallow bupropion, your liver rapidly converts it into several metabolites, and these breakdown products are not inactive leftovers. They circulate in your blood at higher concentrations than the parent drug and contribute meaningfully to the overall effect. The most important metabolite is hydroxybupropion, formed primarily by the liver enzyme CYP2B6. In terms of how bupropion is cleared from the body, the metabolite threohydrobupropion accounts for roughly two-thirds of total clearance, while hydroxybupropion accounts for about a quarter.8PubMed Central. Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4′-OH-bupropion in vitro
The CYP2B6 enzyme is genetically variable. Some people carry a variant called CYP2B6*6 that slows the conversion of bupropion into hydroxybupropion. Carriers of one copy of this variant show moderately reduced hydroxybupropion levels; carriers of two copies show a more pronounced gene-dose effect, with substantially higher bupropion and lower hydroxybupropion in their blood compared to people with the common genotype.9Journal of Pharmacology and Experimental Therapeutics. Influence of CYP2B6 and CYP2C19 Genetic Polymorphisms on Steady-State Bupropion Disposition, Antidepressant Outcomes, and Side Effects This means that two people taking the same dose of bupropion can end up with quite different mixtures of parent drug and metabolites in their systems. Whether this translates into clinically meaningful differences in antidepressant response is an active area of research, but it may partly explain why some people feel noticeably different effects from the same dose.
Reward Sensitivity and Who Responds Best
Bupropion’s dopaminergic emphasis has led researchers to investigate whether it works better in people whose depression involves blunted reward processing, the kind of depression where nothing feels pleasurable or motivating rather than the kind dominated by sadness and anxiety. Brain imaging research has provided some support for this idea.
In a study of patients who had not responded to sertraline (an SSRI), those switched to bupropion showed a specific pattern: patients who had stronger resting-state connectivity between the nucleus accumbens (a core reward hub) and the rostral anterior cingulate cortex responded better to bupropion than those with weaker connectivity. This connectivity was also positively correlated with reward sensitivity itself, meaning people whose brain wiring already predisposed them to process rewards more robustly were the ones who benefited most from bupropion.10PubMed Central. Pretreatment reward sensitivity and frontostriatal resting-state functional connectivity are associated with response to bupropion after sertraline non-response The effect size was large, suggesting this is not a trivial distinction.
This finding fits a broader clinical intuition: bupropion tends to be favored for patients with low-energy, low-motivation presentations of depression, sometimes called “atypical” features that include oversleeping, overeating, and leaden fatigue. The pharmacology makes a plausible case for why. Boosting dopamine and norepinephrine in frontostriatal circuits could restore the motivational “push” that those patients lack, while the absence of serotonergic sedation avoids making the fatigue worse.
Effects on Neurotrophic and Inflammatory Markers
Like many antidepressants, bupropion appears to have effects that go beyond its immediate receptor and transporter activity. One area of growing interest involves brain-derived neurotrophic factor (BDNF), a protein that supports neuron survival and the formation of new connections. In patients with major depression, 12 weeks of bupropion treatment led to a significant increase in serum BDNF levels, from roughly 2.4 to 3.0 ng/ml, in those who responded to treatment.11PubMed. Bupropion monotherapy alters neurotrophic and inflammatory markers in patients of major depressive disorder The same study found that the inflammatory marker TNF-alpha dropped substantially in responders, from about 4.5 to 2.1 pg/ml.
Whether bupropion is directly anti-inflammatory or whether these changes are a downstream consequence of symptom improvement is not fully settled. However, laboratory work has shown that bupropion has direct effects on immune signaling pathways. In cell cultures, bupropion reduced protein levels of several pro-inflammatory molecules, including TNF-alpha and IL-1 beta, while increasing the anti-inflammatory cytokine IL-10. Bupropion also affected the expression of Toll-like receptors (TLR2 and TLR4) and the JAK2/STAT3 signaling pathway, both of which play roles in how the immune system activates and regulates inflammation. The picture is complex because bupropion simultaneously increased the gene expression of some pro-inflammatory molecules while reducing their protein levels, suggesting it modulates inflammation in a nuanced way rather than simply suppressing it across the board.
The Dextromethorphan Combination and Glutamate
Bupropion recently gained a second life as part of a combination drug. In 2022, the FDA approved dextromethorphan-bupropion (brand name Auvelity) for major depressive disorder. This combination exploits a pharmacokinetic trick: dextromethorphan on its own is rapidly broken down by the CYP2D6 liver enzyme, but bupropion and its metabolites are strong inhibitors of CYP2D6. By pairing the two, bupropion slows the metabolism of dextromethorphan enough to keep it circulating at therapeutically useful levels.12PubMed Central. Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder
The point of keeping dextromethorphan around is that it acts on a completely different set of targets. Dextromethorphan is an antagonist at NMDA receptors (a type of glutamate receptor) and an agonist at sigma-1 receptors.12PubMed Central. Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder Glutamate is the brain’s main excitatory neurotransmitter, and NMDA receptor modulation is the same principle behind ketamine’s rapid antidepressant effects. In this combination, bupropion is doing double duty: contributing its own dopamine-norepinephrine effects while simultaneously serving as a metabolic shield for dextromethorphan. The clinical trial data for Auvelity showed faster onset of antidepressant effect compared to bupropion alone, which is consistent with the idea that adding glutamate modulation brings something new to the table.
Blood Pressure and the Norepinephrine Side of Things
Bupropion’s norepinephrine reuptake inhibition has consequences outside the brain. Norepinephrine is the primary neurotransmitter of the sympathetic nervous system, which governs the fight-or-flight response, and raising its levels can influence heart rate and blood vessel tone. Clinical experience confirms that bupropion can lead to blood pressure increases, typically at higher doses. Paradoxically, it may also cause drops in blood pressure upon standing (orthostatic hypotension), particularly in patients who already have cardiovascular disease.13PubMed Central. Antidepressant Drugs Effects on Blood Pressure
This is worth knowing because blood pressure monitoring is rarely routine in psychiatric care, and a modest creep in blood pressure can go unnoticed for months. If you are already borderline hypertensive or on blood pressure medications, bupropion is the kind of antidepressant where periodic checks make sense. The effects are dose-dependent and usually manageable, but they are a real pharmacological consequence of boosting norepinephrine. Interestingly, early animal studies found that intravenous bupropion in dogs did not significantly change arterial pressure or heart rate, which underscores how much the chronic oral dosing context and active metabolites matter for the cardiovascular picture in humans.14PubMed. Bupropion. Effects on cerebral monoamines in rat and on blood pressure in dog
The Low Transporter Occupancy Puzzle
One unresolved question that hangs over bupropion pharmacology is how a drug with only 20-to-26 percent dopamine transporter occupancy produces a clinically meaningful antidepressant effect. Most drugs that work by blocking transporters, including SSRIs, typically need to occupy a much higher percentage of their target transporter to reach clinical efficacy. Several explanations have been proposed, and the honest answer is that no single explanation has been definitively proven.
The leading theory points to bupropion’s metabolites, particularly hydroxybupropion, which has its own norepinephrine transporter blocking activity and accumulates to plasma levels several times higher than the parent drug. The total pharmacological effect is not just bupropion sitting on dopamine transporters; it is a cocktail of the parent drug and at least three or four active metabolites, each with slightly different receptor and transporter affinities, all present simultaneously. Another piece of the puzzle is regional specificity. The PET studies that measured 20-to-26 percent occupancy focused on the striatum, one of the densest dopamine transporter regions in the brain. Bupropion’s effect on dopamine in the prefrontal cortex, where dopamine signaling is more diffuse and the transporter plays a smaller role, could be proportionally larger. In the prefrontal cortex, norepinephrine transporters actually handle a significant share of dopamine clearance, so bupropion’s norepinephrine transporter blockade may be doing double duty there: raising both norepinephrine and dopamine levels.
Add the nicotinic receptor antagonism, the BDNF increase, and the anti-inflammatory effects described above, and the picture starts to look less like one mechanism delivering 100 percent of the antidepressant effect and more like several modest mechanisms converging. Bupropion may be a drug whose clinical potency emerges from the sum of several partial actions rather than from saturating any single target.
Seizure Risk and Dose-Dependent Receptor Engagement
Bupropion’s receptor profile also explains its most serious safety concern. At high doses or in overdose, bupropion lowers the seizure threshold. This risk is dose-dependent and was significant enough that the original immediate-release formulation, prescribed at doses up to 450 mg per day, carried a seizure incidence that led to reformulation into sustained-release and extended-release versions. These newer formulations spread the drug’s absorption over a longer period, avoiding the sharp plasma peaks that are associated with greater seizure risk.
The mechanism behind this seizure liability is not perfectly understood but is thought to involve the drug’s combined effects on catecholamine systems and nicotinic receptors. Excessive dopaminergic and noradrenergic tone can be pro-convulsant, and bupropion’s metabolites, which reach high concentrations and have their own neuroactive properties, may contribute. This is one reason clinicians are cautious about bupropion in patients with eating disorders (electrolyte imbalances lower seizure threshold), heavy alcohol use, or a history of seizures. The receptor profile that makes bupropion activating and energizing at therapeutic doses makes it potentially dangerous when the dose-concentration relationship goes wrong.
How Bupropion Fits Among Antidepressant Mechanisms
The receptor story of bupropion is easiest to appreciate in contrast to the other major antidepressant classes. SSRIs act almost exclusively on the serotonin transporter. SNRIs block both serotonin and norepinephrine transporters. Tricyclic antidepressants hit a broad swath of targets including serotonin transporters, norepinephrine transporters, histamine receptors, muscarinic receptors, and alpha-adrenergic receptors, which is why their side-effect burden is heavy. MAO inhibitors block the enzyme that degrades serotonin, norepinephrine, and dopamine, raising all three but with serious dietary and drug-interaction restrictions.
Bupropion carves out its niche by raising dopamine and norepinephrine without touching serotonin, without blocking histamine or muscarinic receptors, and with an additional nicotinic antagonist action that no other standard antidepressant shares. That combination of what it does and what it avoids defines everything distinctive about the drug: the energizing rather than sedating quality, the minimal sexual side effects, the appetite-neutral to slightly appetite-suppressing profile, the smoking-cessation utility, and the seizure risk at high doses. Understanding the receptor targets is not just pharmacology trivia; it maps directly onto the clinical experience of taking the drug.